Insertion/deletion polymorphism in the promoter of NFKB1 influences severity but not mortality of acute respiratory distress syndrome.
OBJECTIVE
This study investigated whether the insertion/deletion polymorphism in the promoter of NFKB1 is associated with severity and/or mortality in ARDS.


METHODS
Prospective study in a mixed anesthesiological ICU of the University Hospital Essen.


METHODS
103 adult patients with ARDS (white Germans).


RESULTS
Patients with ARDS were genotyped for the insertion/deletion polymorphism in the promoter of NFKB1 (-94ins/delATTG). In ARDS patients genotypes differed significantly between those with severe ARDS [Lung Injury Score (LIS)>or=3; 23 homozygote deletion (DD), heterozygote (ID) 31, and homozygote insertion wildtype (II) 23], and those with LIS below 3 (1 DD, 9 ID, 16 II). Likewise, the frequency of the D allele was significantly less in patients with higher LIS (50% D) than lower LIS (21% D). Using these values produces a significantly higher OR of 16.0 (95% CI 1.96-130.9) for DD than for II, while the OR for ID vs. II was 2.4 (95% CI 0.9-6.4). Genotypes of the NFKB1 promoter polymorphism were associated neither with 30-day survival nor with duration of ICU stay.


CONCLUSIONS
The insertion/deletion polymorphism in the promoter of NFKB1 influences the severity but not the mortality of ARDS.
Adamzik
Michael
M
Institut für Pharmakogenetik, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. Michael.adamzik@uni-duisburg-essen.de.|Klinik für Anästhesiologie und Intensivmedizin, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. Michael.adamzik@uni-duisburg-essen.de.
Frey
Ulrich H
UH
Institut für Pharmakogenetik, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.|Klinik für Anästhesiologie und Intensivmedizin, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Rieman
Kathrin
K
Institut für Pharmakogenetik, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Sixt
Stephan
S
Klinik für Anästhesiologie und Intensivmedizin, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Beiderlinden
Martin
M
Klinik für Anästhesiologie und Intensivmedizin, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Siffert
Winfried
W
Institut für Pharmakogenetik, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Peters
Jürgen
J
Klinik für Anästhesiologie und Intensivmedizin, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
D000328:Adult; D005260:Female; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D054643:INDEL Mutation / Q000235:genetics*; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D052002:NF-kappa B p50 Subunit / Q000235:genetics*; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic / Q000235:genetics*; D011446:Prospective Studies; D012128:Respiratory Distress Syndrome / Q000235:genetics* / Q000401:mortality / Q000503:physiopathology
D052002:NF-kappa B p50 Subunit; C489548:NFKB1 protein, human